The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

FDA is expected to issue Emergency Use Authorization for Moderna’s vaccine, enabling immediate distribution.

FDA Advisors Recommend Moderna’s COVID-19 Vaccine

The company has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to the people of Singapore. 

Moderna Enters into Supply Agreement to Provide Singapore with its COVID-19 Vaccine

The HERALD trial will involve participants 18 years and older who will receive a two-dose schedule of CVnCoV or placebo at multiple sites is Europe and Latin America.

CureVac Enrolls First Participant in COVID-19 Vaccine Candidate Trial 

A report, launched by Takeda UK, has shown that despite the increase in media attention, COVID-19 has had little positive impact on the perception of pharmaceutical companies. 

Report Reveals the Pandemic had Little Positive Impact on Pharma Reputation

EUA marks a milestone in COVID-19 vaccine development and is hailed as a turning point in pandemic fight. 

First COVID-19 Vaccine Heads to US Patients

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Success in combatting the pandemic depends on the ability of manufacturers to quickly and efficiently produce and distribute the huge quantities of vaccines demanded by the United States government and public health organizations around the world. 

Vaccine Scale-up and Production Key to Combatting Pandemic

Committee recommends Emergency Use Authorization of first mRNA-based COVID-19 vaccine; FDA approval is pending.

Pfizer-BioNTech Vaccine Moves Closer to EUA

The European Medicines Agency has launched a full investigation into a cyberattack. 

EMA Launches Investigation into Cyberattack

The company has received $500 million in funding from Sino Biopharmaceutical for further development, capacity expansion, and manufacturing of CoronaVac, its COVID-19 vaccine candidate.

Sinovac Biotech Receives $500 Million in Funding for COVID-19 Vaccine Manufacturing  

CDMO HALIX will manufacture the drug substance for AstraZeneca’s COVID-19 vaccine candidate, AZD1222, at commercial scale at its cGMP facility in the Netherlands.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success